Century Therapeutics, Inc.
NASDAQ: IPSC. Canonical company identity and public leadership record.
US
- Alpha ID
- alpha:company:fe9bd09c-3fa0-42b1-a05c-51a6eb7b1f4d
- SEC CIK
- 0001850119
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 18, 2026
- Newest evidence
- Apr 27, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Brent PfeiffenbergerSince Apr 27, 2026
- Chair
- Brent Pfeiffenberger, Pharm.D.
- Independent
- Not published5 directors published
- Published claims
- 222 distinct sources
- Evidence records
- 70 pinned
- Source conflicts
- 0None open
Built from 2 distinct sources and 7 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
EXECUTIVE APPOINTED
Adrienne Farid executive of Century Therapeutics, Inc., effective 2026-04-27.
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Chief Scientific Officer | Adrienne Farid | Apr 2026 | current | Source reportedE4 |
| President and Chief Executive Officer | Brent Pfeiffenberger | Apr 2026 | current | Source reportedE5 |
| Chief Operating Officer | Chad Cowan | Apr 2026 | current | Source reportedE6 |
| Chief Technology Officer | Gregory Russotti | Apr 2026 | current | Source reportedE7 |
| President and Chief Executive Officer | Brent Pfeiffenberger, Pharm.D. | Not captured | unknown | Source reportedE2 |
| Chief Scientific Officer | Chad Cowan, Ph.D. | Not captured | unknown | Source reportedE2 |
| Principal Finance Officer, Senior Vice President of Finance | Douglas Carr | Not captured | unknown | Source reportedE2 |
| Chief Technology and Manufacturing Officer | Gregory Russotti, Ph.D. | Not captured | unknown | Source reportedE2 |
Board of directors
Evidence5 directors published. Independence determinations are not published for every director.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Alessandro Riva | Independence not published | 2021 | None published | Source reportedE3 |
| Brent Pfeiffenberger | Independence not published | 2023 | None published | Source reportedE3 |
| Daphne Quimi | Independence not published | 2022 | None published | Source reportedE3 |
| Kimberly Blackwell | Independence not published | 2021 | None published | Source reportedE3 |
| Martin Murphy | Independence not published | 2025 | None published | Source reportedE3 |
| Alessandro Riva, M.D. | Independent | Not published | None published | Source reportedE2 |
| Brent Pfeiffenberger, Pharm.D. | Not independentChair | Not published | Chief Executive Officer and Chairman of the Board | Source reportedE2 |
| Han Lee, Ph.D., M.B.A. | Independent | Not published | None published | Source reportedE2 |
| Kimberly Blackwell, M.D. | Independent | Not published | None published | Source reportedE2 |
| Martin Murphy, Ph.D. | Independent | Not published | None published | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Chief Executive Officer and Chairman of the Board | Not published | Brent Pfeiffenberger, Pharm.D. | Not described in the published record |
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Financials and market context
EvidenceGovernance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Adrienne FaridChief Scientific Officercompany:fe9bd09c-3fa0-42b1-a05c-51a6eb7b1f4d:leadership_role:15
- Brent PfeiffenbergerPresident and Chief Executive Officer; Directorcompany:fe9bd09c-3fa0-42b1-a05c-51a6eb7b1f4d:leadership_role:16, company:fe9bd09c-3fa0-42b1-a05c-51a6eb7b1f4d:leadership_role:8
- Chad CowanChief Operating Officercompany:fe9bd09c-3fa0-42b1-a05c-51a6eb7b1f4d:leadership_role:18
- Gregory RussottiChief Technology Officercompany:fe9bd09c-3fa0-42b1-a05c-51a6eb7b1f4d:leadership_role:21
- Brent Pfeiffenberger, Pharm.D.President and Chief Executive Officer; President, Chief Executive Officer and Chairman of the Boardcompany:fe9bd09c-3fa0-42b1-a05c-51a6eb7b1f4d:leadership_role:17, company:fe9bd09c-3fa0-42b1-a05c-51a6eb7b1f4d:leadership_role:5
- Chad Cowan, Ph.D.Chief Scientific Officercompany:fe9bd09c-3fa0-42b1-a05c-51a6eb7b1f4d:leadership_role:19
- Douglas CarrPrincipal Finance Officer, Senior Vice President of Financecompany:fe9bd09c-3fa0-42b1-a05c-51a6eb7b1f4d:leadership_role:20
- Gregory Russotti, Ph.D.Chief Technology and Manufacturing Officercompany:fe9bd09c-3fa0-42b1-a05c-51a6eb7b1f4d:leadership_role:22
- Alessandro RivaDirectorcompany:fe9bd09c-3fa0-42b1-a05c-51a6eb7b1f4d:leadership_role:6
- Daphne QuimiDirectorcompany:fe9bd09c-3fa0-42b1-a05c-51a6eb7b1f4d:leadership_role:9
- Kimberly BlackwellDirectorcompany:fe9bd09c-3fa0-42b1-a05c-51a6eb7b1f4d:leadership_role:11
- Martin MurphyDirectorcompany:fe9bd09c-3fa0-42b1-a05c-51a6eb7b1f4d:leadership_role:13
- Alessandro Riva, M.D.Directorcompany:fe9bd09c-3fa0-42b1-a05c-51a6eb7b1f4d:leadership_role:7
- Han Lee, Ph.D., M.B.A.Directorcompany:fe9bd09c-3fa0-42b1-a05c-51a6eb7b1f4d:leadership_role:10
- Kimberly Blackwell, M.D.Directorcompany:fe9bd09c-3fa0-42b1-a05c-51a6eb7b1f4d:leadership_role:12
- Martin Murphy, Ph.D.Directorcompany:fe9bd09c-3fa0-42b1-a05c-51a6eb7b1f4d:leadership_role:14
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 7 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 18, 2026. Cited by 4 Claims.
- E2sec def 14a. Published Apr 27, 2026. Retrieved Sep 6, 2026. Cited by 9 Claims.
- E3sec proxy. Published Apr 27, 2026. Retrieved Sep 2, 2026. Cited by 5 Claims.
- E4sec filing. Published Apr 27, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
- E5sec filing. Published Apr 27, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
- E6sec filing. Published Apr 27, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
- E7sec filing. Published Apr 27, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 18, 2026- Adrienne Farid executive of Century Therapeutics, Inc., effective 2026-04-27.
- Brent Pfeiffenberger executive of Century Therapeutics, Inc., effective 2026-04-27.
- Chad Cowan executive of Century Therapeutics, Inc., effective 2026-04-27.
- Gregory Russotti executive of Century Therapeutics, Inc., effective 2026-04-27.
- Martin Murphy seat on Century Therapeutics, Inc., effective 2025-01-01.
- Brent Pfeiffenberger seat on Century Therapeutics, Inc., effective 2023-01-01.
- Daphne Quimi seat on Century Therapeutics, Inc., effective 2022-01-01.
- Alessandro Riva seat on Century Therapeutics, Inc., effective 2021-01-01.
- Kimberly Blackwell seat on Century Therapeutics, Inc., effective 2021-01-01.



